Positive results of RENOTORCH trial of the anti PD1 Toripalimab + Axitinib vs Sunitinib favoring the combination was presented by Dr X Zheng @ESMO. While PFS was significant, I consider this a “lateral pass” (making a football analogy), and not a forward pass in the current era